Abstract
Cardiovascular Diseases (CVD) remain the leading cause of mortality and morbidity worldwide. To date, significant progress has been made in developing stimuli-responsive nanosystems that can intrinsically interact with pathological microenvironment to achieve site-specific delivery along with on-demand drug release for precise CVD treatment. Herein, this review summarizes recent advances on smart nanosystems in response to a wide range of biological cues, including pH, enzymes, ROS, shear force, ATP, etc., which can boost drug delivery performance or monitor disease progression in a non-invasive manner. The designs, compositions and main outcomes of the single and multi-responsive nanosystems for drug delivery and/or detection purposes are provided and discussed.
Keywords: Biologically responsive, nanosystems, nanoparticle, drug delivery, stimuli-triggered drug release, cardiovascular diseases.
Current Drug Delivery
Title:Biologically Responsive Nanosystems Targeting Cardiovascular Diseases
Volume: 18 Issue: 7
Author(s): Zhiling Song, Kechen Song, Yi Xiao, Hui Guo, Yizhun Zhu*Xiaolin Wang*
Affiliation:
- State Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, Taipa, Macao,China
- State Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, Taipa, Macao,China
Keywords: Biologically responsive, nanosystems, nanoparticle, drug delivery, stimuli-triggered drug release, cardiovascular diseases.
Abstract: Cardiovascular Diseases (CVD) remain the leading cause of mortality and morbidity worldwide. To date, significant progress has been made in developing stimuli-responsive nanosystems that can intrinsically interact with pathological microenvironment to achieve site-specific delivery along with on-demand drug release for precise CVD treatment. Herein, this review summarizes recent advances on smart nanosystems in response to a wide range of biological cues, including pH, enzymes, ROS, shear force, ATP, etc., which can boost drug delivery performance or monitor disease progression in a non-invasive manner. The designs, compositions and main outcomes of the single and multi-responsive nanosystems for drug delivery and/or detection purposes are provided and discussed.
Export Options
About this article
Cite this article as:
Song Zhiling , Song Kechen , Xiao Yi , Guo Hui , Zhu Yizhun *, Wang Xiaolin *, Biologically Responsive Nanosystems Targeting Cardiovascular Diseases, Current Drug Delivery 2021; 18 (7) . https://dx.doi.org/10.2174/1567201818666210127093743
DOI https://dx.doi.org/10.2174/1567201818666210127093743 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Design and Synthesis of Thiazolidinedione Derivates as Selective PPARγ Modulators
Letters in Drug Design & Discovery Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets G-Protein Coupled Receptor Resensitization - Appreciating the Balancing Act of Receptor Function
Current Molecular Pharmacology Global Cardiovascular Risk Management in Primary Prevention
Current Vascular Pharmacology Urine IL-18 is a Biomarker of Early Acute Kidney Injury (AKI)
Recent Patents on Biomarkers Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Lipid Nanoformulations for Oral Delivery of Bioactives: An Overview
Current Drug Therapy Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia
Current Pharmaceutical Design Recent Advances in Transcatheter Aortic Valve Implantation: Novel Devices and Potential Shortcomings
Current Cardiology Reviews MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets L-Arginine in the Prevention and Treatment of Cardiovascular Disease: From Basic to Clinical Research Studies
Vascular Disease Prevention (Discontinued)